Clinical

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

Racial and geographic CRC disparities described in a recent report highlight the need for urgent research and prevention efforts nationwide.

The results are the latest from the multiarm EPCORE-NHL-2 trial, which has studied the bispecific antibody epcoritamab in multiple uses and combinations.

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and emerging outcome measures.

Persistent high-level EBNA-1 peptide antibody titers could be used to identify multiple sclerosis (MS) vs neuromyelitis optica spectrum disorder (NMOSD).

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

The efficacy and safety of efgartigimod in pediatric patients will need to be further validated with future studies.

Meta-analysis across B-cell lymphomas shows zanubrutinib (Brukinsa) delivers higher ORR/CR than acalabrutinib (Calquence) or ibrutinib among BTK inhibitors.

Federal RHTP funding often misses states with the highest rural mortality and greatest projected Medicaid funding losses, researchers found.

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd Schlesinger, MD.

A deeper understanding of vitiligo's autoimmune mechanisms has fundamentally transformed vitiligo care, explains Susan Taylor, MD.

Phase 3 trials show deucravacitinib, the first TYK2 inhibitor approved for adults with active psoriatic arthritis (PsA), improves both joint and skin symptoms.

April Armstrong, MD, MPH, discusses choosing AD therapies, JAK inhibitor safety, response measures, and emerging treatments shaping the field.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

The FDA approved kinase inhibitors, biologics, a pancreatic cancer device, GLP-1 updates, and a new ultrarare disease pathway in February 2026.

The politicization of public health is eroding vaccine confidence, risking lower uptake and potential disease outbreaks, says Noel T. Brewer, PhD.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years in terms of clinical practice change?

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What updates to KDIGO will likely need to be made in view of these novel therapies being approved? How should payers and health systems think differently about treating this disease?

Immunotherapies are transforming treatment and improving outcomes for patients with advanced cSCC, according to Todd Schlesinger, MD.

The rise in CRC in adults younger than 65 underscores the need for early screening and prevention efforts.

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide.

Bidisha Mandal, PhD, concluded her conversation with AJMC by emphasizing the need for policy support and further research to maximize telehealth's impact.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.